Benazepril combined with either amlodipine or hydrochlorothiazide is more effective than monotherapy for blood pressure control and prevention of end-organ injury in hypertensive Dahl rats.
Benazepril combined with either amlodipine or hydrochlorothiazide is more effective than monotherapy for blood pressure control and prevention of end-organ injury in hypertensive Dahl rats.
复制标题
贝那普利与氨氯地平或氢氯噻嗪联合使用比单一疗法更有效地控制高血压 Dahl 大鼠的血压和预防终末器官损伤。
DOI：
10.1097/01.fjc.0000238598.09152.30
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
Raij,Leopoldo
中科院分区：
文献类型：
--
作者：
Zhou,Ming-Sheng;Jaimes,EdgarA;Raij,Leopoldo
我们研究了氢氯噻嗪（HCTZ）、血管紧张素转换酶抑制剂苯那普利、钙通道阻滞剂氨氯地平、或苯那普利/氨氯地平或苯那普利/HCTZ联合使用对高血压达尔盐敏感大鼠收缩压（BP）和终末器官损伤（左心室肥厚、蛋白尿和内皮依赖性乙酰胆碱松弛）的影响，这些大鼠分别给予正常盐（0.5% NaCl）或高盐（4% NaCl）饮食6周。喂食高盐饮食的大鼠出现高血压和明显的终末器官损伤。单药治疗HCTZ（饮用水75mg /L）或氨氯地平（灌胃10mg /kg/天）可降低收缩压和蛋白尿；苯那普利（40mg /kg/天灌胃）可降低蛋白尿，但未显著降低收缩压。在接受高盐饮食的大鼠中，只有HCTZ减轻了左心室肥厚，而氨氯地平和苯那普利改善了内皮依赖性松弛，而HCTZ没有。苯那普利与氨氯地平或HCTZ联合使用可显著降低收缩压和终末器官损伤。这些数据清楚地支持临床研究，表明联合治疗在控制收缩压和预防终末器官损伤方面比单一治疗更有效。不同类型的降压药物的互补作用机制似乎对血压和终末器官损伤有更大的益处。
We studied the effect of hydrochlorothiazide (HCTZ), the angiotensin-converting enzyme inhibitor benazepril, the calcium channel blocker amlodipine, or a combination of benazepril/amlodipine or benazepril/HCTZ on systolic blood pressure (BP) and end-organ injury (left ventricular hypertrophy, proteinuria, and endothelium-dependent relaxation to acetylcholine) in hypertensive Dahl salt-sensitive rats fed either a normal-salt (0.5% NaCl) or high-salt (4% NaCl) diet for 6 weeks. Rats fed a high-salt diet developed hypertension and significant end-organ injury. Monotherapy with HCTZ (75 mg/L in drinking water) or amlodipine (10 mg/kg/day by gavage) reduced systolic BP and proteinuria; benazepril (40 mg/kg/day by gavage) decreased proteinuria without significantly lowering systolic BP. In rats receiving a high-salt diet, only HCTZ reduced left ventricular hypertrophy, whereas endothelium-dependent relaxation was improved by amlodipine and benazepril but not by HCTZ. Combining benazepril with either amlodipine or HCTZ dramatically reduced systolic BP and end-organ injury. These data clearly support clinical studies suggesting that combination therapy is more effective than monotherapy for systolic BP control and prevention of end-organ injury. Complementary mechanisms of action of agents from different antihypertensive classes appear to facilitate the greater benefit on BP and end-organ injury.